LeMaitre projects $276.3M 2026 revenue amid 11% organic growth outlook and Artegraft expansion (NASDAQ:LMAT)
· seekingalpha.com
LeMaitre Vascular (LMAT) Q2 2026 earnings call recap: Artegraft growth, lowered guidance, FX/export delays, supply risks, and 2026 outlook—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...